💊Executive Order on Lowering Drug Prices and Its Business Implications
Executive Order 14273 seeks to restore prior initiatives aimed at lowering prescription drug prices in the U.S. The order emphasizes transparency in drug pricing, encourages competition through generics, and addresses the Medicare Drug Price Negotiation Program to enhance access to affordable medications while fostering innovation in the pharmaceutical industry.
Learn More📊Request for Comments on National Sample Survey of Registered Nurses
The Department of Commerce, in accordance with the Paperwork Reduction Act (PRA) of 1995, invites the general public and other Federal agencies to comment on proposed, and continuing information collections, which helps us to assess the impact of our information collection requirements and minimize the public's reporting burden. The purpose of this notice is to allow for 60 days of public comment on the proposed reinstatement, with change, of National Sample Survey of Registered Nurses (NSSRN), prior to the submission of the information collection request (ICR) to OMB for approval.
Learn More🏥New VA Application Process for Extended Care Services
In compliance with the Paperwork Reduction Act (PRA) of 1995, this notice announces that the Veterans Health Administration (VHA), Department of Veterans Affairs (VA), will submit the collection of information abstracted below to the Office of Management and Budget (OMB) for review and comment. The PRA submission describes the nature of the information collection and its expected cost and burden, and it includes the actual data collection instrument.
Learn More🏥FY 2025 Supplemental Funding for National Suicide Prevention Lifeline
This notice is to inform the public that the Substance Abuse and Mental Health Services Administration (SAMHSA) is supporting a supplement (in scope of the parent award) for the Cooperative Agreement for National Suicide Prevention Lifeline and Disaster Distress Helpline recipient, Mental Health Association of New York City, Inc. (DBA Vibrant Emotional Health), funded in FY 2021 under Notice of Funding Opportunity (NOFO) SM 21-005. The recipient may receive up to $100,000,000 and has a project end date of September 2026. The supplemental funding will be used to maintain 988 operations and services, both at local levels and across all subnetwork services. This funding will ensure continuation of all 988 services and supports.
Learn More⚖️DEA Suspends Dentist's Registration Over Compliance Violations
The Drug Enforcement Administration has issued an Order to Show Cause and suspended the registration of Lona Bibbs-Walker, D.D.S., citing inadequate records on controlled substances and lack of state authority to practice. The order illustrates critical compliance issues in the healthcare industry, emphasizing the importance of strict adherence to regulatory standards.
Learn More⚖️DEA Denies Moustafa Aboshady's Registration Application
The Drug Enforcement Administration (DEA) issued an Order to Show Cause, proposing the denial of Dr. Moustafa M. Aboshady's DEA registration application. The basis for this denial stems from his mandatory exclusion from Medicare, Medicaid, and all Federal health care programs due to previous legal convictions related to false statements in healthcare benefits programs. The Agency concluded that substantial evidence supported the denial of his application for registration.
Learn More💊Medicaid and CHIP Information Collection Comment Request Overview
On May 28, 2010, the Office of Management and Budget (OMB) issued Paperwork Reduction Act (PRA) guidance related to the "generic" clearance process. Generally, this is an expedited process by which agencies may obtain OMB's approval of collection of information requests that are "usually voluntary, low-burden, and uncontroversial collections," do not raise any substantive or policy issues, and do not require policy or methodological review. The process requires the submission of an overarching plan that defines the scope of the individual collections that would fall under its umbrella. This Federal Register notice seeks public comment on one or more of our collection of information requests that we believe are generic and fall within the scope of the umbrella. Interested persons are invited to submit comments regarding our burden estimates or any other aspect of this collection of information, including: the necessity and utility of the proposed information collection for the proper performance of the agency's functions, the accuracy of the estimated burden, ways to enhance the quality, utility and clarity of the information to be collected, and the use of automated collection techniques or other forms of information technology to minimize the information collection burden.
Learn More⚖️DEA Revocation of Registration
The Drug Enforcement Administration (DEA) revoked Ajumobi Agu, M.D.'s registration due to sustained illegal activity, including dispensing controlled substances without appropriate licenses. The order emphasizes the importance of compliance with both federal and state laws in the healthcare field, and the potential consequences for practitioners engaged in similar misconduct.
Learn More⚖️Revocation of Medical Registration
The Drug Enforcement Administration issued an Order to Show Cause for the revocation of Dr. Henry-Norbert O. Ndekwe's registration due to his lack of authority to handle controlled substances in Oklahoma. The document outlines the legal processes regarding the revocation and highlights the implications for healthcare practitioners and businesses in the industry.
Learn More💊Key Medicare and Medicaid Regulatory Changes for 2026
This final rule revises the Medicare Advantage (Part C), Medicare Prescription Drug Benefit (Part D), Medicare cost plan, and Programs of All-Inclusive Care for the Elderly (PACE) regulations to implement changes related to prescription drug coverage, the Medicare Prescription Payment Plan, dual eligible special needs plans (D-SNPs), Part C and D Star Ratings, and other programmatic areas, including the Medicare Drug Price Negotiation Program. This final rule also codifies existing sub-regulatory guidance in the Part C and Part D programs.
Learn More